[go: up one dir, main page]

SI1766012T1 - Protismiselni antibakterijski postopek in spojina - Google Patents

Protismiselni antibakterijski postopek in spojina

Info

Publication number
SI1766012T1
SI1766012T1 SI200531354T SI200531354T SI1766012T1 SI 1766012 T1 SI1766012 T1 SI 1766012T1 SI 200531354 T SI200531354 T SI 200531354T SI 200531354 T SI200531354 T SI 200531354T SI 1766012 T1 SI1766012 T1 SI 1766012T1
Authority
SI
Slovenia
Prior art keywords
bases
compound
bacterial
antisense compounds
mrna
Prior art date
Application number
SI200531354T
Other languages
English (en)
Inventor
Bruce L Geller
Jesse D Deere
Patrick L Iversen
Original Assignee
Avi Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avi Biopharma Inc filed Critical Avi Biopharma Inc
Publication of SI1766012T1 publication Critical patent/SI1766012T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65613Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. cephalosporins and analogs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • C12N2310/3145Phosphoramidates with the nitrogen in 3' or 5'-position
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3233Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
SI200531354T 2004-07-02 2005-07-01 Protismiselni antibakterijski postopek in spojina SI1766012T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58511204P 2004-07-02 2004-07-02
EP05857499A EP1766012B1 (en) 2004-07-02 2005-07-01 Antisense antibacterial method and compound
PCT/US2005/023553 WO2006085973A2 (en) 2004-07-02 2005-07-01 Antisense antibacterial method and compound

Publications (1)

Publication Number Publication Date
SI1766012T1 true SI1766012T1 (sl) 2011-10-28

Family

ID=36686070

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531354T SI1766012T1 (sl) 2004-07-02 2005-07-01 Protismiselni antibakterijski postopek in spojina

Country Status (12)

Country Link
US (4) US8314072B2 (sl)
EP (2) EP2351839A3 (sl)
AT (1) ATE510914T1 (sl)
AU (1) AU2005327188C8 (sl)
CA (2) CA2571593C (sl)
CY (1) CY1111765T1 (sl)
DK (1) DK1766012T3 (sl)
ES (1) ES2367289T3 (sl)
PL (1) PL1766012T3 (sl)
PT (1) PT1766012E (sl)
SI (1) SI1766012T1 (sl)
WO (1) WO2006085973A2 (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
PL1766012T3 (pl) * 2004-07-02 2011-11-30 Avi Biopharma Inc Antysensowne, przeciwbakteryjne związki i sposoby
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
WO2007009094A2 (en) * 2005-07-13 2007-01-18 Avi Biopharma, Inc. Antisense antibacterial method and compound
US8067571B2 (en) * 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
AU2007257094B2 (en) * 2006-05-05 2012-10-25 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of SGLT2
JP2010505741A (ja) * 2006-05-10 2010-02-25 エイブイアイ バイオファーマ, インコーポレイテッド カチオン性のサブユニット間結合を有するオリゴヌクレオチドアナログ
EA200900741A1 (ru) * 2006-11-27 2010-04-30 Айзис Фармасьютикалз, Инк. Способы лечения гиперхолестеринемии
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
KR20200133284A (ko) 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
HUE054179T2 (hu) * 2010-06-23 2021-08-30 Curna Inc Nátriumcsatornás, feszültségfüggõ, alfa alegységgel (SCNA) kapcsolatos betegségek kezelése a természetes antiszensz (SCNA)-transzkripció gátlásával
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CA2817090A1 (en) * 2010-11-12 2012-05-18 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
MX2013009191A (es) 2011-02-08 2013-11-04 Charlotte Mecklenburg Hospital Oligonucleotidos antisentido.
BR112014011875B1 (pt) 2011-11-18 2022-01-04 Sarepta Therapeutics, Inc Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos
BR112014023347A2 (pt) 2012-03-20 2017-07-18 Sarepta Therapeutics Inc conjugados de ácido borônico de análogos oligonucleotídeos
EP3143141B1 (en) 2014-05-16 2019-10-02 Oregon State University Antisense antibacterial compounds and methods
JP6687542B2 (ja) 2014-05-19 2020-04-22 オレゴン ステート ユニバーシティ アンチセンス抗菌化合物および方法
WO2016003816A1 (en) * 2014-07-01 2016-01-07 The University Of North Carolina At Chapel Hill Small molecules that enhance the activity of oligonucleotides
EP3240794A4 (en) * 2014-12-31 2018-10-31 Oregon State University Antisense antibacterial compounds and methods
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
CA3010084A1 (en) 2015-12-23 2017-06-29 Oregon State University Antisense antibacterial compounds and methods

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
EP0216860B1 (en) 1985-03-15 1992-10-28 SUMMERTON, James Stereoregular polynucleotide-binding polymers
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
DE69034213T2 (de) 1989-12-20 2006-08-24 Avi Biopharma, Inc., Portland Ungeladene, auf morpholin basierende polymere mit chiralen, phosphor enthaltenden brücken zwischen den untereinheiten
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
JPH06501843A (ja) 1990-08-14 1994-03-03 アイシス・ファーマシューティカルス・インコーポレーテッド アンチセンスオリゴヌクレオチドによるインフルエンザa型ウイルス,アン・アーバh2n2株の阻害
AU659482B2 (en) 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US6030954A (en) 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5821052A (en) 1992-04-16 1998-10-13 University Of Medicine And Dentistry Of New Jersey Control of the synthesis of proteins by anitisense RNA-tRNA complex
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6060456A (en) 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US5479847A (en) * 1994-11-07 1996-01-02 Marlen Research Corporation Dual-piston pump apparatus
GB9505438D0 (en) 1995-03-17 1995-05-03 Sod Conseils Rech Applic Antisense oligonucleotides
GB9510718D0 (en) * 1995-05-26 1995-07-19 Sod Conseils Rech Applic Antisense oligonucleotides
AU729643B2 (en) 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
AU3811897A (en) 1996-07-24 1998-02-10 Oglios Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
US6124271A (en) 1997-01-24 2000-09-26 Avi Biopharma, Inc. Method and conjugate for treating H. pylori infection
EP0975370B9 (en) 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6204019B1 (en) 1997-06-04 2001-03-20 Smithkline Beecham Corporation Sec A2 from Streptococcus pneumoniae
US6610539B1 (en) 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
EP0894857A3 (en) 1997-08-01 2001-09-26 Smithkline Beecham Corporation SecA gene from Streptococcus pneumoniae
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6228579B1 (en) 1997-11-14 2001-05-08 San Diego State University Foundation Method for identifying microbial proliferation genes
US6548651B1 (en) 1998-11-11 2003-04-15 Pantheco A/S Modified peptide nucleic acid (PNA) molecules
JP2002535015A (ja) 1999-01-29 2002-10-22 エイブイアイ バイオファーマ, インコーポレイテッド 標的rnaを検出するための非侵襲性方法
US7094765B1 (en) 1999-01-29 2006-08-22 Avi Biopharma, Inc. Antisense restenosis composition and method
US6521438B1 (en) * 1999-11-05 2003-02-18 North Carolina State University Chemoreceptors in plant parasitic nematodes
US20030095953A1 (en) * 1999-11-12 2003-05-22 Myles C. Cabot Methods of reversing drug resistance in cancer cells
US6677153B2 (en) 1999-11-29 2004-01-13 Avi Biopharma, Inc. Antisense antibacterial method and composition
JP2003518946A (ja) * 2000-01-04 2003-06-17 エイブイアイ バイオファーマ, インコーポレイテッド アンチセンス抗細菌性細胞分裂組成物、およびその方法
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
EP1296718A1 (en) 2000-04-06 2003-04-02 Pantheco A/S Pharmaceutical composition of modified pna molecules
JP2003533986A (ja) * 2000-05-04 2003-11-18 エイブイアイ バイオファーマ, インコーポレイテッド スプライス領域アンチセンス組成物および方法
US6841542B2 (en) 2000-07-06 2005-01-11 Avi Biopharma, Inc. Transforming growth factor beta (TGF-β) blocking agent-treated stem cell composition and method
AU2002214127B2 (en) * 2000-10-27 2007-06-07 J. Craig Venter Institute, Inc. Nucleic acids and proteins from streptococcus groups A and B
WO2002079467A2 (en) 2001-03-29 2002-10-10 Københavns Universitet Antibiotic-free bacterial strain selection with antisense molecules
US20030125241A1 (en) * 2001-05-18 2003-07-03 Margit Wissenbach Therapeutic uses of LNA-modified oligonucleotides in infectious diseases
US20030224353A1 (en) * 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
US6828105B2 (en) 2001-10-16 2004-12-07 Avi Biopharma, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
WO2004041854A2 (en) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
US7468418B2 (en) 2003-04-29 2008-12-23 Avi Biopharma., Inc. Compositions for enhancing transport of molecules into cells
US7666612B2 (en) * 2003-05-23 2010-02-23 Epfl-Ecole Polytechnique Federale De Lausanne Methods for protein labeling based on acyl carrier protein
EP1654363B1 (en) 2003-08-05 2010-12-15 AVI BioPharma, Inc. Oligonucleotide analog and method for treating flavivirus infections
US7402574B2 (en) 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
PL1766012T3 (pl) 2004-07-02 2011-11-30 Avi Biopharma Inc Antysensowne, przeciwbakteryjne związki i sposoby
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US7790694B2 (en) 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
WO2007009094A2 (en) 2005-07-13 2007-01-18 Avi Biopharma, Inc. Antisense antibacterial method and compound
JP2010505741A (ja) 2006-05-10 2010-02-25 エイブイアイ バイオファーマ, インコーポレイテッド カチオン性のサブユニット間結合を有するオリゴヌクレオチドアナログ
US10100305B2 (en) 2011-07-15 2018-10-16 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites

Also Published As

Publication number Publication date
AU2005327188A1 (en) 2006-08-17
EP1766012B1 (en) 2011-05-25
CY1111765T1 (el) 2015-10-07
DK1766012T3 (da) 2011-09-19
ATE510914T1 (de) 2011-06-15
US7625873B2 (en) 2009-12-01
CA2571593A1 (en) 2006-08-17
AU2005327188B2 (en) 2011-03-17
WO2006085973A2 (en) 2006-08-17
EP2351839A3 (en) 2011-10-05
PL1766012T3 (pl) 2011-11-30
CA2571593C (en) 2015-04-21
US20070049542A1 (en) 2007-03-01
AU2005327188C1 (en) 2011-07-07
AU2005327188C9 (en) 2011-09-22
US20130289091A1 (en) 2013-10-31
US9534220B2 (en) 2017-01-03
ES2367289T3 (es) 2011-11-02
CA2875436A1 (en) 2006-08-17
EP1766012A2 (en) 2007-03-28
EP2351839A2 (en) 2011-08-03
AU2005327188C8 (en) 2011-09-22
WO2006085973A3 (en) 2007-04-12
US20100137408A1 (en) 2010-06-03
US20070021362A1 (en) 2007-01-25
PT1766012E (pt) 2011-09-05
US8314072B2 (en) 2012-11-20

Similar Documents

Publication Publication Date Title
CY1111765T1 (el) Αντινοηματικη αντιβακτηριακη μεθοδος και ενωση
WO2007009094A3 (en) Antisense antibacterial method and compound
DE69934242D1 (de) Polyketid synthase enzyme und rekombinante dna konstrukte dafür, zur herstellung von mit fk-506 und fk-520 verwandten verbindungen
WO2007051045A3 (en) Compositions and methods for inhibiting expression of huntingtin gene
WO2007056326A3 (en) Compositions and methods for inhibiting expression of nav1.8 gene
WO2009104001A3 (en) Oligopeptidic compounds and uses thereof
WO2005066202A3 (en) Bacillus cry9 family members
PL1776455T3 (pl) Enzym lipolityczny, jego zastosowania w przemyśle spożywczym
WO2004065580A3 (en) Mesecnhymal stem cells as a vehicle for ion channel transfer in syncytial structures
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
DK1472344T3 (da) Bakteriofaglysin
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
WO2004016754A3 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
BR9905785A (pt) Processo de fermantação para a preparação de ácido d-panto-tênico utilizando cepas da famìlia enterobacteriaceae
ATE514718T1 (de) Peptabody für krebsbehandlung
HK1159988A1 (en) Compositions and methods for inhibiting expression of factor v leiden mutant gene
EP1248633A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF GLYCOGEN SYNTHASE KINASE 3 BETA
AU2007208928A8 (en) Transgenic plant transformed with stress-responsive gene
WO2002101065A3 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
WO2003023044A3 (en) Process for the production of l-amino acids using coryneform bacteria
WO2009109102A8 (en) Recombinant microorganism and method for producing l-lysine
WO2004016749A3 (en) Antisense modulation of acyl-coa synthetase 1 expression
WO2005023186A3 (en) Methods of identifying agents that inhibit the growth of cancer cells
WO2003097789A3 (en) Farnesyl diphosphate synthase from pseudomonas aeruginosa